ERS 2020 — Long-term dupilumab well tolerated in patients with asthma


  • Antara Ghosh
  • Conference Reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In patients with moderate-severe asthma, long-term treatment with dupilumab was well tolerated, with a long-term safety profile consistent with that observed in short-term parent trials.
  • Among nonoral corticosteroid (OCS)-dependent patients, dupilumab maintained the clinical efficacy observed in parent studies, including a persistently low exacerbation rate and sustained improvement in lung function.

Why this matters

  • Efficacy and safety of dupilumab up to 1 year have already been demonstrated.

Study design

  • LIBERTY ASTHMA TRAVERSE, open-label extension (OLE) study evaluated 2282 patients with moderate-to-severe asthma or OCS-dependent severe asthma, who completed a previous dupilumab asthma study (P2b DRI, EXPEDITION, QUEST, or VENTURE).
  • Patients received add-on subcutaneous dupilumab (300 mg) every 2 weeks up to 96 weeks.
  • Treatment-emergent adverse events (TEAEs), annualized exacerbations rate (AER) of severe asthma during the treatment period, and change from parent study baseline in forced expiratory volume in 1 second (FEV1) up to week 96 were evaluated.
  • Funding: GSK, Sanofi.

Key results

  • Rate of TEAEs in overall population of the parent study was as follows:
    • P2b: 75%-83%;
    • QUEST: 81%-83%; and
    • VENTURE: 62%-64%.
  • Rates of TEAEs in OLE were similar to those observed in the parent study with no new safety signal identified in patients from:
    • P2b: placebo/dupilumab, 79.3%; dupilimab/dupilumab, 87.6%;
    • QUEST: placebo/dupilumab, 80.1%; dupilimab/dupilumab, 77.9%; and
    • VENTURE: placebo/dupilumab, 76.3%; dupilimab/dupilumab, 77.8%.
  • Serious adverse events were experienced by 9%-13% of patients.
  • TEAEs leading to treatment discontinuation were low.
  • The low unadjusted AER observed in the parent study among non-OCS-dependent patients was maintained in OLE:
    • P2b: placebo/dupilumab, 0.314; dupilimab/dupilumab, 0.330; and
    • QUEST: placebo/dupilumab, 0.351; dupilimab/dupilumab, 0.331.
  • Improvements in FEV1 observed in the parent study among the non-OCS population were sustained during the OLE (mean FEV1 at week 96, 2.02-2.12 L; mean percent change from parent study baseline, 13%-22%).

Limitations

  • Open-label design.